ALNY
Alnylam Pharmaceuticals Inc
3월 13일 4:00 PM ET (한국 3/14 05:00)
$313.41
-3.82 ▼ -1.20%
🌙 3월 13일 6:45 PM ET (한국 3/14 07:45)
$313.55
+0.14 ▲ +0.04%
| Index | NDX | P/E | 138.86 | EPS (ttm) | 2.26 | Insider Own | 0.88% | Shs Outstand | 0.13B | Perf Week | -2.26% |
| Market Cap | 41.57B | Forward P/E | 28.91 | EPS next Y | 58.45% | Insider Trans | -10.2% | Shs Float | 0.13B | Perf Month | -2.75% |
| Enterprise Value | 41.63B | PEG | 0.34 | EPS next Q | 0.99 | Inst Own | 98.17% | Short Float | 3.48% | Perf Quarter | -22.51% |
| Income | 0.31B | P/S | 11.19 | EPS this Y | 193.67% | Inst Trans | -0.74% | Short Ratio | 3 | Perf Half Y | -33.11% |
| Sales | 3.71B | P/B | 52.57 | EPS next 5Y | 84.05% | ROA | 6.73% | Short Interest | 4.57M | Perf YTD | -21.18% |
| Book/sh | 5.96 | P/C | 14.29 | EPS past 3/5Y | - | ROE | 73.28% | 52W High | -36.76% ($495.55) | Perf Year | 29.64% |
| Cash/sh | 21.93 | P/FCF | 89.32 | Sales past 3/5Y | 52.98% 49.77% | ROIC | 8.98% | 52W Low | 52.24% ($205.87) | Perf 3Y | 69.54% |
| Dividend Est. | - | EV/EBITDA | 74.7 | EPS Y/Y TTM | 209.06% | Gross Margin | 81.64% | Volatility(W/M) | 2.98% 3.52% | Perf 5Y | 120.4% |
| Dividend TTM | - | EV/Sales | 11.21 | Sales Y/Y TTM | 65.19% | Oper. Margin | 13.51% | ATR (14) | 11.02 | Perf 10Y | 404.28% |
| Dividend Ex-Date | - | Quick Ratio | 2.71 | EPS Q/Q | 310.87% | Profit Margin | 8.45% | RSI (14) | 36.6 | Recom | 1.62 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.76 | Sales Q/Q | 84.95% | SMA20 | -3.84% ($325.93) | Beta | 0.4 | Target Price | $458.78 |
| Payout | - | Debt/Eq | 3.76 | Earnings | 2000000 | SMA50 | -9.64% ($346.85) | Rel Volume | 0.54 | Prev Close | $317.23 |
| Employees | 2500 | LT Debt/Eq | 3.43 | EPS/Sales Surpr. | -29.06% -4.53% | SMA200 | -20.07% ($392.11) | Avg Volume(3M) | 1.53M | Price | $313.41 |
| IPO | 2004/5/28 | Option/Short | Yes/Yes | Trades | 18248 | Volume | 829,276 | Change | -1.2% |
뉴스 로딩 중...